Intercept Pharma (ICPT) Misses Q1 EPS by 14c

Intercept Pharma (NASDAQ: ICPT) reported Q1 EPS of ($0.77), $0.14 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $67.96 million versus the consensus estimate of $72.33 million.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery